Development of Integrated In-Process Monitoring to Enable High Throughput Cell and Gene Therapy Manufacturing

Ori正在开发下一代商业规模生产细胞和基因疗法（CGT）的解决方案。CAR-T细胞疗法是CGT的一种，已被证明在治疗危及生命的疾病（包括血癌）方面非常有效，并在实体瘤方面有很大的希望;但是，在此情况下，这些治疗方法的制造存在巨大的问题。这些问题导致患者获得这些潜在生命的机会有限-拯救疗法该项目的重点是技术的发展，使治疗能够以最高的效率和最高的质量，最快的吞吐量。这将解决目前在生产CGT，特别是CAR-T细胞疗法方面遇到的巨大挑战。Ori的愿景是为患有侵袭性癌症和其他严重疾病的患者提供这些挽救生命的疗法。Ori技术将通过改进制造方式和降低成本来实现这一访问，目前成本极高（每个治疗剂量约为17.5万英镑）。

Ori are developing the next generation of solutions for manufacturing cell and gene therapies (CGT) at commercial scale.CAR-T cell therapies are a type of CGT that have been shown to be incredibly effective in treating life-threatening conditions, including blood cancers and holds great hope in solid tumours; however, there are huge problems in the way these therapies are manufactured.These problems are leading to patients having limited access to these potentially life-saving therapies. This project focusses on the development of technology that will allow therapies to be made with maximum efficiency and to the highest quality, with the fastest throughput. This will address huge challenges currently encountered with manufacturing CGT and specifically, CAR-T cell therapies.Ori's vision is to enable access to these life-saving therapies for patients suffering from aggressive forms of cancer and other serious conditions. Ori technology will enable this access by improving how manufacturing is carried out and reducing the cost, which is currently extremely high (about £175K per therapy dose made).